Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0DPCBX
ADC Name
HcHAb18-DM1
Synonyms
HcHAb18 DM1; HcHAb18DM1
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Non-small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
3.43-3.68
Antibody Name
HcHAb18
  Antibody Info 
Antigen Name
Basigin (BSG)
  Antigen Info 
Payload Name
Mertansine DM1
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
Combination Type
Emtansine
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 8 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 23.23
%
A-549 cells
Lung adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 23.23
%
A-549 cells
Lung adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 38.63
%
A-549 cells
Lung adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 56.95
%
A-549 cells
Lung adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 89.22
%
A-549 cells
Lung adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 94.2
%
NCI-H226 cells
Pleural epithelioid mesothelioma
Tumor Growth Inhibition value (TGI) 
≈ 95.84
%
A-549 cells
Lung adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 97.4
%
NCI-H460 cells
Lung large cell carcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.46
ug/mL
NCI-H226 cells
Pleural epithelioid mesothelioma
Half Maximal Inhibitory Concentration (IC50) 
0.77
ug/mL
NCI-H460 cells
Lung large cell carcinoma
Half Maximal Inhibitory Concentration (IC50) 
1.96
ug/mL
NCI-H520 cells
Lung squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50) 
18.26
ug/mL
A-549 cells
Lung adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 8 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 23.23% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (1 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 23.23% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (2 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 38.63% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (4 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 56.95% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (8 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 89.22% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (16 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 94.2% (Day 29) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (30 mg/kg, i.v. injection weekly in a total 4 doses) induces efficient tumor cell killing in cell line-derived models of NCI-H226 cells with CD147 expression with high expression.
In Vivo Model NCI-H226 CDX model
In Vitro Model Pleural epithelioid mesothelioma NCI-H226 cells CVCL_1544
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 95.84% (Day 27) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (32 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of A549 cells with CD147 expression with high expression.
In Vivo Model A549 CDX model
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 97.40% (Day 14) Positive CD147 expression (CD147 +++/++)
Method Description
HcHAb18-DM1 (18 mg/kg, twice a week for 4 weeks) induces efficient tumor cell killing in cell line-derived models of NCI-H460 cells with CD147 expression with high expression.
In Vivo Model NCI-H460 CDX model
In Vitro Model Lung large cell carcinoma NCI-H460 cells CVCL_0459
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.46 ug/mL Positive CD147 expression (CD147 +++/++)
Method Description
In vitro efficacy of HcHAb18-DM1 versus HcHAb18 and IgG1-DM1 on six cell lines treated for 72 h.
In Vitro Model Pleural epithelioid mesothelioma NCI-H226 cells CVCL_1544
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.77 ug/mL Positive CD147 expression (CD147 +++/++)
Method Description
In vitro efficacy of HcHAb18-DM1 versus HcHAb18 and IgG1-DM1 on six cell lines treated for 72 h.
In Vitro Model Lung large cell carcinoma NCI-H460 cells CVCL_0459
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.96 ug/mL Positive CD147 expression (CD147 +++/++)
Method Description
In vitro efficacy of HcHAb18-DM1 versus HcHAb18 and IgG1-DM1 on six cell lines treated for 72 h.
In Vitro Model Lung squamous cell carcinoma NCI-H520 cells CVCL_1566
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 18.26 ug/mL Positive CD147 expression (CD147 +++/++)
Method Description
In vitro efficacy of HcHAb18-DM1 versus HcHAb18 and IgG1-DM1 on six cell lines treated for 72 h.
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
References
Ref 1 A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer. Biochem Biophys Res Commun. 2019 Jun 11;513(4):1083-1091. doi: 10.1016/j.bbrc.2019.04.046. Epub 2019 Apr 19.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.